Skip to main content
Fig. 2 | BMC Cancer

Fig. 2

From: Erlotinib as single agent first line treatment in locally advanced or metastatic activating EGFR mutation-positive lung adenocarcinoma (CEETAC): an open-label, non-randomized, multicenter, phase IV clinical trial

Fig. 2

Kaplan-Meier analysis of progression-free survival. (a) The intent-to-treat cohort had a 12.8 months median PFS. (b) Never smoker patients had increased progression-free survival. (c) Patients with extrathoracic metastasis at the time of screening had lower PFS than patients with pulmonary metastasis. (d) ECOG2 patients demonstrated progression earlier when compared to ECOG1 or ECOG0 performance status

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us